AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31279078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Omeprazole and Placebo)
Number of subjects: 86
Study 30670313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin‐C dissolved in an alkaline wash plus rifampicin
Number of subjects: 50
Study 30670313 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin and alkaline nasal wash
Number of subjects: 50
Study 28277054 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for erythema migrans (specific regimens not detailed in the abstract)
Number of subjects: 188
Study 28277054 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for erythema migrans
Number of subjects: 188
Study 25758598 — intervention group
Group type: EXPERIMENTAL
Intervention: Action research process using the social educational process known as PLA
Number of subjects: 0
Study 23835707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² on day 1 of 21-day cycles; n = 359)
Number of subjects: 539
Study 23835707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 180)
Number of subjects: 539
Study 21736786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration plus a diuretic (DD; 40 mg furosemide)
Number of subjects: 26
Study 21736786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration plus placebo (DN)
Number of subjects: 26
Study 21736786 — intervention group
Group type: COMPARATOR
Intervention: Exercise while maintaining euhydration plus placebo (EU; control condition)
Number of subjects: 26
Study 19756431 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy
Number of subjects: 0
Study 19756431 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 19756431 — intervention group
Group type: EXPERIMENTAL
Intervention: Response evaluation or prediction after neoadjuvant chemotherapy
Number of subjects: 0
Study 16777385 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment responders
Number of subjects: 0
Study 16777385 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 0
Study 16777385 — intervention group
Group type: COMPARATOR
Intervention: Adherent patients
Number of subjects: 0
Study 16777385 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent patients
Number of subjects: 0
Study 15305227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mU/l prolactin
Number of subjects: 5
Study 15305227 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng/ml leptin
Number of subjects: 5
Study 15305227 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolactin
Number of subjects: 5
Study 15305227 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 5
Study 10402679 — intervention group
Group type: EXPERIMENTAL
Intervention: Mimicry by confederates of participants' posture and movements
Number of subjects: 0
Study 10402679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositionally empathic individuals
Number of subjects: 0
Study 10402679 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor behavior of participants
Number of subjects: 0
Study 7578537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail distribution of health education materials
Number of subjects: 512
Study 7578537 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner distribution of health education materials
Number of subjects: 512
Study 7578537 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived acceptability of materials (both groups)
Number of subjects: 512
Study 2126147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (2 x 150 mg)
Number of subjects: 8
Study 2126147 — intervention group
Group type: COMPARATOR
Intervention: Enprostil (2 x 35 micrograms)
Number of subjects: 8
Study 7466216 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncrossed reaction times
Number of subjects: 20
Study 7466216 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed reaction times
Number of subjects: 20
Study 7466216 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus eccentricity
Number of subjects: 20
Study 7466216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal hemiretina stimulation at 35°
Number of subjects: 20
Study 7466216 — intervention group
Group type: EXPERIMENTAL
Intervention: Global speed of the two hemiretinas
Number of subjects: 20
Study 29969700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 302
Study 29969700 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 302
Study 27806213 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser intra‐hemorrhoidal coagulation
Number of subjects: 0
Study 27806213 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy
Number of subjects: 0
Study 27806213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 24769014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) maintenance therapy, 10 mg daily, given on days 1 to 21 of 28-day cycles for 12 months after alloHCT.
Number of subjects: 30
Study 22176632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI meals consumed predominantly late (supper)
Number of subjects: 6
Study 22176632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI meals consumed predominantly early (breakfast)
Number of subjects: 6
Study 22176632 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy consumed in the evening meal pattern
Number of subjects: 6
Study 22176632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI diet consumed predominantly early in the day
Number of subjects: 6
Study 19948383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg
Number of subjects: 29
Study 19948383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 20mg
Number of subjects: 29
Study 19948383 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 0mg (placebo)
Number of subjects: 29
Study 17622361 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 20
Study 17622361 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 20
Study 15737169 — intervention group
Group type: EXPERIMENTAL
Intervention: Porridge group (fruit- and fibre-rich porridge)
Number of subjects: 20
Study 11888836 — intervention group
Group type: EXPERIMENTAL
Intervention: Two daily subcutaneous injections of hexarelin (1.5 microg/kg)
Number of subjects: 6
Study 11888836 — intervention group
Group type: EXPERIMENTAL
Intervention: Three daily subcutaneous injections of hexarelin (1.5 microg/kg)
Number of subjects: 6
Study 11888836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hexarelin (1 microg/kg) at the end of each 24-h sampling period
Number of subjects: 6
Study 11888836 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior hexarelin administration
Number of subjects: 6
Study 11888836 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 6
Study 10442376 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2 plus calcium folinate 90 mg (divided into three doses per day)
Number of subjects: 0
Study 10442376 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel starting at 50 mg/m2, escalated in 10 mg/m2 steps
Number of subjects: 0
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 25 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 35 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 50 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 60 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 75 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 90 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 100 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 115 mg three times a day
Number of subjects: 48
Study 8522637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2189709 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic drainage (drain placed)
Number of subjects: 113
Study 2189709 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic drainage (no drain placed)
Number of subjects: 113
Study 6459255 — intervention group
Group type: EXPERIMENTAL
Intervention: HNN cream (halcinonide, neomycin, and nystatin)
Number of subjects: 154
Study 6459255 — intervention group
Group type: EXPERIMENTAL
Intervention: BGI cream (betamethasone valerate, gentamicin, iodochlorhydroxyquin, and tolnaftate)
Number of subjects: 154
Study 6459255 — intervention group
Group type: EXPERIMENTAL
Intervention: HNN cream
Number of subjects: 154
Study 6459255 — intervention group
Group type: EXPERIMENTAL
Intervention: BGI cream
Number of subjects: 154
Study 31378863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20-30 training
Number of subjects: 60
Study 31378863 — intervention group
Group type: COMPARATOR
Intervention: 30-30 training
Number of subjects: 60
Study 28160355 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral VIM-DBS
Number of subjects: 16
Study 28160355 — intervention group
Group type: COMPARATOR
Intervention: Unilateral right-hemispheric VIM-DBS
Number of subjects: 16
Study 28160355 — intervention group
Group type: COMPARATOR
Intervention: Unilateral left-hemispheric VIM-DBS
Number of subjects: 16
Study 28160355 — intervention group
Group type: COMPARATOR
Intervention: Inactivated VIM-DBS
Number of subjects: 16
Study 28160355 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllable duration
Number of subjects: 16
Study 26331880 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.325 g/kg)
Number of subjects: 20
Study 26331880 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.65 g/kg)
Number of subjects: 20
Study 26331880 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration (0.00 g/kg)
Number of subjects: 20
Study 26331880 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.00 g/kg)
Number of subjects: 20
Study 25608549 — intervention group
Group type: EXPERIMENTAL
Intervention: Military Mental Health Promotion Program (email based cognitive behavioral intervention)
Number of subjects: 32
Study 25608549 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-equivalent control group)
Number of subjects: 32
Study 21853694 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) Programme
Number of subjects: 0
Study 21853694 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19730388 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 30
Study 19730388 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 30 mg
Number of subjects: 30
Study 19730388 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (both doses)
Number of subjects: 30
Study 17540218 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Disclosure (ED) intervention
Number of subjects: 59
Study 17540218 — intervention group
Group type: COMPARATOR
Intervention: Standard control writing intervention
Number of subjects: 59
Study 16763926 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP (Transabdominal Preperitoneal)
Number of subjects: 82
Study 16763926 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP (Totally Extraperitoneal)
Number of subjects: 82
Study 16763926 — intervention group
Group type: COMPARATOR
Intervention: Open Lichtenstein hernioplasty
Number of subjects: 82
Study 16763926 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP and TEP
Number of subjects: 82
Study 15190235 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to a maximum dose of 2,400 mg/d in three doses)
Number of subjects: 20
Study 15190235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10913030 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (DWL, n = 14)
Number of subjects: 52
Study 10913030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (EWL, n = 14)
Number of subjects: 52
Study 10913030 — intervention group
Group type: COMPARATOR
Intervention: Control (C, n = 8)
Number of subjects: 52
Study 10913030 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with weight maintenance (EWS, n = 16)
Number of subjects: 52
Study 8843294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime
Number of subjects: 0
Study 8843294 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study 1839998 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral preparation of medroxyprogesterone acetate (200‐mg sachet, twice daily)
Number of subjects: 22
Study 1839998 — intervention group
Group type: COMPARATOR
Intervention: Standard formulation (Farlutal, 500‐mg tablet, twice daily)
Number of subjects: 22
Study 1839998 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral preparation of medroxyprogesterone acetate
Number of subjects: 22
Study 6133977 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 0
Study 6133977 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 0
Study 30508132 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceived organizational resources
Number of subjects: 253
Study 30508132 — intervention group
Group type: EXPERIMENTAL
Intervention: Better staff motivation
Number of subjects: 253
Study 28799443 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized education on environmental fall prevention recommendations
Number of subjects: 24
Study 28799443 — intervention group
Group type: COMPARATOR
Intervention: Generalized education on environmental fall prevention recommendations
Number of subjects: 24
Study 26976734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 40
Study 26976734 — intervention group
Group type: COMPARATOR
Intervention: High FODMAP diet
Number of subjects: 40
Study 26316042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/low-carbohydrate diet (diet HP)
Number of subjects: 193
Study 26316042 — intervention group
Group type: COMPARATOR
Intervention: Standard hypocaloric diet (diet S)
Number of subjects: 193
Study 24573334 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to Scottish Intercollegiate Guidelines Network guideline for the diagnosis and assessment of ASD after medical training
Number of subjects: 90
Study 24573334 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial specialist appointment diagnosis of ASD
Number of subjects: 90
Study 24573334 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of recommended discretionary structured observational instrument
Number of subjects: 90
Study 22906140 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5-ms waveform
Number of subjects: 121
Study 22906140 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5-ms waveform
Number of subjects: 121
Study 19387901 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB) - losartan (25‐50 mg, n = 5), candesartan (4‐8 mg, n = 4), valsartan (80 mg, n = 1), telmisartan (40 mg, n = 2), olmesartan (10 mg, n = 1)
Number of subjects: 13
Study 19387901 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 13
Study 17460018 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 100
Study 17460018 — intervention group
Group type: COMPARATOR
Intervention: RV apical pacing
Number of subjects: 100
Study 15293073 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional influenza split vaccine (SpV)
Number of subjects: 840
Study 15293073 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted subunit vaccine (aSuV)
Number of subjects: 840
Study 15293073 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome‐based subunit vaccine (vSuV)
Number of subjects: 840
Study 15293073 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 840
Study 11450720 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable tonometer prism
Number of subjects: 100
Study 11450720 — intervention group
Group type: COMPARATOR
Intervention: Standard Goldmann tonometer prism
Number of subjects: 100
Study 9491898 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable patients during hemodialysis
Number of subjects: 30
Study 9491898 — intervention group
Group type: COMPARATOR
Intervention: Unstable patients during hemodialysis
Number of subjects: 30
Study 9491898 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable patients
Number of subjects: 30
Study 9491898 — intervention group
Group type: COMPARATOR
Intervention: Unstable patients
Number of subjects: 30
Study 8113059 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH intervention targeting cardiovascular health behaviors (dietary intake of fat and sodium, physical activity, tobacco use)
Number of subjects: 0
Study 8113059 — intervention group
Group type: COMPARATOR
Intervention: Control schools (not specified)
Number of subjects: 0
Study 3245857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the morning
Number of subjects: 0
Study 3245857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the evening
Number of subjects: 0
Study 3245857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30198163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 27993435 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified patient education program
Number of subjects: 424
Study 27993435 — intervention group
Group type: COMPARATOR
Intervention: Usual lecture-based education program
Number of subjects: 424
Study 26093863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin recapture therapy given orally 12 and 2 hours before CABG
Number of subjects: 2630
Study 26093863 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2630
Study 26093863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin recapture therapy
Number of subjects: 2630
Study 23732189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (60 mg/day duloxetine + 300 mg/day pregabalin)
Number of subjects: 804
Study 23732189 — intervention group
Group type: COMPARATOR
Intervention: High-dose monotherapy (120 mg/day duloxetine or 600 mg/day pregabalin)
Number of subjects: 804
Study 23732189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 804
Study 23732189 — intervention group
Group type: COMPARATOR
Intervention: High-dose monotherapy
Number of subjects: 804
Study 23732189 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day duloxetine
Number of subjects: 804
Study 22137511 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tranexamic acid 10 mg/kg
Number of subjects: 84
Study 22137511 — intervention group
Group type: COMPARATOR
Intervention: Sterile water 0.1 mL/kg (placebo group)
Number of subjects: 84
Study 19329697 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 100
Study 19329697 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 100
Study 16997399 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging
Number of subjects: 0
Study 16997399 — intervention group
Group type: COMPARATOR
Intervention: Standard echocardiography
Number of subjects: 0
Study 15105234 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 degrees-rotation group, n = 24
Number of subjects: 48
Study 15105234 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 24
Number of subjects: 48
Study 12133743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 94
Study 12133743 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 94
Study 10426682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 14
Study 10426682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7497205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic attack (TIA)
Number of subjects: 646
Study 7497205 — intervention group
Group type: EXPERIMENTAL
Intervention: Male
Number of subjects: 646
Study 7497205 — intervention group
Group type: EXPERIMENTAL
Intervention: Female
Number of subjects: 646
Study 2321721 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25% (1 ml/kg)
Number of subjects: 43
Study 2321721 — intervention group
Group type: COMPARATOR
Intervention: Rectal diclofenac 0.25 mg/kg
Number of subjects: 43
Study 6985789 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus selective intra‐arterial vasopressin infusion
Number of subjects: 38
Study 6985789 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 38
Study 30744647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program intervention 1
Number of subjects: 0
Study 30744647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program intervention 2
Number of subjects: 0
Study 30744647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28645058 — intervention group
Group type: EXPERIMENTAL
Intervention: Free physical activity classes over a 6-month period
Number of subjects: 1445
Study 28645058 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent user program with prizes for park visits
Number of subjects: 1445
Study 28645058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both free physical activity classes and frequent user program
Number of subjects: 1445
Study 28645058 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control condition)
Number of subjects: 1445
Study 26491815 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention during the trial (DCAS)
Number of subjects: 268